You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 122 No. 2, February 2004 TABLE OF CONTENTS
  Archives
  •  Online Features
  Laboratory Sciences
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on Web of Science (1)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Ocular/ Adnexal Tumors
 •Pediatric Ophthalmology
 •Radiation Therapy
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

External Beam Radiation "Salvage" Therapy in Transgenic Murine Retinoblastoma

Lucia Sobrin, MD; Brandy C. Hayden, BS; Timothy G. Murray, MD; Nicole Cicciarelli; Ingrid U. Scott, MD, MPH; Eleut Hernandez; Xiaodong Wu, PhD; Arnold M. Markoe, MD; William Feuer, MS; Lilia Fulton, BA; Joan M. O'Brien, MD

Arch Ophthalmol. 2004;122:251-257.

Objective  To determine the efficacy of low-dose "salvage" external beam radiation therapy (EBRT) following failed subconjunctival carboplatin chemotherapy in a murine model of heritable retinoblastoma.

Methods  Eighty-four eyes from 8-week-old, simian virus 40, T-antigen–positive mice were treated with 6 serial subconjunctival carboplatin injections (100 µg/25 µL). At 12 weeks of age, 64 eyes received EBRT for a total dose of 480 (4.8 Gy), 1200 (12.0 Gy), 1560 (15.6 Gy), or 3000 (30.0 Gy) rad. Twenty eyes received no additional therapy following subconjunctival carboplatin injections. Ten eyes received a total dose EBRT of only 3000 rad. Eight eyes received subconjuctival injections of only an isotonic sodium chloride solution. Ten eyes served as untreated controls.

Main Outcome Measures  Eyes were enucleated at 20 weeks to assess the presence of tumor on histopathological examination.

Results  Salvage therapy using low-dose EBRT was able to reestablish tumor control in a dose-dependent manner. Increasing the EBRT dose to 3000 rad resulted in 100% tumor control. The dose-dependent curves were significantly different between the treatment groups—EBRT alone vs salvage EBRT after receiving subconjunctival carboplatin injections (P<.001).

Conclusion  Low-dose hyperfractionated salvage EBRT following failed primary subconjunctival carboplatin chemotherapy is efficacious in the treatment of retinoblastoma in this animal model.

Clinical Relevance  Salvage EBRT using a reduced total radiation dose could be associated with a radiation-related treatment enhancement in pediatric retinoblastoma.


From the Bascom Palmer Eye Institute, Department of Ophthalmology, University of Miami, Miami, Fla (Drs Sobrin, Murray, Scott, Wu, and Markoe, Mss Hayden and Cicciarelli, and Messrs Hernandez and Feuer); and the Department of Ophthalmology, University of California, San Francisco (Ms Fulton and Dr O'Brien). The authors have no relevant financial interest in this article.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2004 American Medical Association. All Rights Reserved.